EGFR and non-small cell lung carcinoma: Despite improvements in surgical techniques and availability of new highly targeted therapies such as EGFR-directed tyrosine kinase inhibitors (TKIs), the prognosis of NSCLC remains still very poor with a 5-year survival rate about 15% which is only 5% higher than the survival rate 40 years ago [4].